CN1177843C - 新的查耳酮 - Google Patents

新的查耳酮 Download PDF

Info

Publication number
CN1177843C
CN1177843C CNB008123039A CN00812303A CN1177843C CN 1177843 C CN1177843 C CN 1177843C CN B008123039 A CNB008123039 A CN B008123039A CN 00812303 A CN00812303 A CN 00812303A CN 1177843 C CN1177843 C CN 1177843C
Authority
CN
China
Prior art keywords
phenyl
compound
methyl
propen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008123039A
Other languages
English (en)
Chinese (zh)
Other versions
CN1371372A (zh
Inventor
E����ķ�͵���
E·博姆巴德利
P·瓦伦蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN1371372A publication Critical patent/CN1371372A/zh
Application granted granted Critical
Publication of CN1177843C publication Critical patent/CN1177843C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB008123039A 1999-09-03 2000-08-28 新的查耳酮 Expired - Fee Related CN1177843C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920910.8A GB9920910D0 (en) 1999-09-03 1999-09-03 Novel chalcones
GB9920910.8 1999-09-03

Publications (2)

Publication Number Publication Date
CN1371372A CN1371372A (zh) 2002-09-25
CN1177843C true CN1177843C (zh) 2004-12-01

Family

ID=10860346

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008123039A Expired - Fee Related CN1177843C (zh) 1999-09-03 2000-08-28 新的查耳酮

Country Status (21)

Country Link
US (1) US6620842B2 (enExample)
EP (1) EP1212315B1 (enExample)
JP (1) JP2003508527A (enExample)
KR (1) KR100819576B1 (enExample)
CN (1) CN1177843C (enExample)
AT (1) ATE235483T1 (enExample)
AU (1) AU776226B2 (enExample)
CA (1) CA2382130A1 (enExample)
CZ (1) CZ2002787A3 (enExample)
DE (1) DE60001851T2 (enExample)
DK (1) DK1212315T3 (enExample)
ES (1) ES2193106T3 (enExample)
GB (1) GB9920910D0 (enExample)
HK (1) HK1043999B (enExample)
HU (1) HUP0202579A3 (enExample)
NO (1) NO20021049L (enExample)
PL (1) PL353064A1 (enExample)
PT (1) PT1212315E (enExample)
RU (1) RU2252938C2 (enExample)
SK (1) SK3112002A3 (enExample)
WO (1) WO2001017988A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101052816B1 (ko) 2002-04-17 2011-07-29 스미스 클라인 비참 코포레이션 화합물, 조성물 및 방법
US7638554B2 (en) * 2002-04-18 2009-12-29 Sri International Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
US20030229136A1 (en) * 2002-04-18 2003-12-11 Nurulain Zaveri Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
JP2005533119A (ja) 2002-07-17 2005-11-04 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
US6864264B1 (en) 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
CN100336797C (zh) * 2005-08-19 2007-09-12 浙江大学 四取代查耳酮衍生物及制备方法和用途
CN104169267B (zh) * 2012-03-01 2017-03-01 香港理工大学 含炔烃的类黄酮、含叠氮化物的类黄酮和含三唑的类黄酮作为调节剂用于癌症的多药耐药

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI912995A0 (fi) * 1988-12-21 1991-06-19 Upjohn Co Atiaterosklerotiska och antirombotiska 1-benzopyran-4-oner och 2-amino-1,3-benzoxazin-4-oner.
US5023341A (en) * 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US4996230A (en) * 1990-02-16 1991-02-26 Eli Lilly And Company Leukotriene antagonists
JPH05509078A (ja) * 1990-05-17 1993-12-16 ベイラー カレッジ オブ メディシン 成長抑制因とガンおよび細胞増殖性疾患措置法
IT1271301B (it) * 1994-12-20 1997-05-27 Indena Spa Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders

Also Published As

Publication number Publication date
SK3112002A3 (en) 2003-10-07
EP1212315B1 (en) 2003-03-26
CZ2002787A3 (cs) 2002-06-12
KR20020031598A (ko) 2002-05-02
HUP0202579A3 (en) 2003-07-28
GB9920910D0 (en) 1999-11-10
NO20021049L (no) 2002-05-03
CN1371372A (zh) 2002-09-25
PT1212315E (pt) 2003-08-29
AU7510900A (en) 2001-04-10
JP2003508527A (ja) 2003-03-04
DE60001851T2 (de) 2003-12-11
HK1043999A1 (en) 2002-10-04
RU2252938C2 (ru) 2005-05-27
HUP0202579A2 (hu) 2002-11-28
NO20021049D0 (no) 2002-03-01
US20030055056A1 (en) 2003-03-20
PL353064A1 (en) 2003-10-06
WO2001017988A1 (en) 2001-03-15
ES2193106T3 (es) 2003-11-01
US6620842B2 (en) 2003-09-16
HK1043999B (en) 2003-08-15
AU776226B2 (en) 2004-09-02
KR100819576B1 (ko) 2008-04-22
CA2382130A1 (en) 2001-03-15
DK1212315T3 (da) 2003-06-23
DE60001851D1 (de) 2003-04-30
ATE235483T1 (de) 2003-04-15
EP1212315A1 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
CN1046731C (zh) 吡咯并[2,3-d]嘧啶类化合物及其应用
FR2567885A1 (fr) Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant
CA2722258C (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
CN1142927C (zh) 查耳酮香豆素类
CN1726190A (zh) 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－羰基－1h－吲哚－1－基乙酸衍生物
CN1198802C (zh) 具有抗增殖活性的查耳酮类化合物
CN1142227A (zh) 新的噻唑烷-4-酮衍生物
CN1177843C (zh) 新的查耳酮
CN1179158A (zh) 4－氨基－3－酰基二氮杂萘衍生物
CA3050255A1 (en) Inhibitors of the n-terminal domain of the androgen receptor
JP2012504588A (ja) ピリミド誘導体およびその製薬学的用途
CN1227538A (zh) 含有4－氧代－丁酸的药物组合物
CN1241921C (zh) 含氟异黄酮衍生物、制造方法及其用途
CN1301987C (zh) 7－羧基－黄酮衍生物、其制备方法和应用
JP2010526812A (ja) 炎症性疾患の治療のためのスピロ化合物
JP6943239B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
CN1281603C (zh) 作为抗炎药的氨基吡咯化合物
JP7302090B2 (ja) ベンゾフラン系ｎ－アシルヒドラゾン誘導体およびそれを含む薬学的組成物
CN1974545A (zh) 长链脂肪酰胺类化合物及其应用
JP2007537979A (ja) トコフェロールに加えて他の少なくとも１種の薬活性材料も含有する化学化合物
CN106243130A (zh) 3,6‑二芳基‑[1,2,4]三氮唑并[3,4‑b][1,3,4]噻二嗪类化合物及其用途
CN1113909A (zh) 查尔酮酸类化合物及其制法和作为药物的用途
CN1150420A (zh) 4-喹啉酮衍生物及其盐
CN118388357A (zh) 一种含杂原子查尔酮衍生物及其制备方法与应用
CN1029737C (zh) 新氨烷基酮衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee